Entity

Time filter

Source Type


Fan Z.,Third Peoples Hospital of Dalian | Tian X.F.,Dalian Medical University | Tang S.X.,Dalian University | Zhang Y.Y.,Third Peoples Hospital of Dalian | And 2 more authors.
Medicine (United States) | Year: 2014

A liposarcoma is the most common type of soft tissue sarcoma, and most liposarcomas are malignant. The extremities are the most common site for liposarcomas. There are 5 histologic types of liposarcoma, as follows: well differentiated; myxoid; round cell; pleomorphic; and dedifferentiated. Myxoid liposarcomas (MLSs) represent a subgroup of liposarcomas. There has been no report of MLSs in the abdominal wall.We report a rare case of a MLS of a 43-year-old male who presented with tensile force on the abdominal wall. Computed tomography (CT) found a tumor in abdominal wall. There was no other abnormal symptom and the laboratory testing was also unusual.At last, the tumor was successfully excised, which was diagnosed MLSs in pathology. Following standard principles, after complete excision, the patient received radiotherapy. The patient was followed up for 8 month and no disease recurrence was identified.MLSs are rarely seen in the clinic, irrespective of the presenting signs, but also based on histologic features. The aim of this report was to present the differential diagnosis of an abdominal wall mass, and to remind us of MLSs. Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins. Source


Bo L.V.,Third Peoples Hospital of Dalian
Journal of Dalian Medical University | Year: 2013

Objective To observe the therapeutic effect of Insulin Aspart 30 combined with Voglibose in treating type 2 diabetes mellitus. Methods 80 patients with type 2 diabetes mellitus were randomly divided into two groups. 40 patients in control group were treated with Insulin Aspart 30 and the other patients in observation group were treated with Insulin Aspart 30 combined with Voglibose, with a treatment course of 2 weeks for both groups. Fasting blood glucose( FBG) , 2 hours postprandial blood glucose (2hPBG) , daily dosage of insulin and incidence of hypoglycemia were detected after treatment. Results After 2 weeks, the 2hPBG was (8. 39 ± 1.88) mmol/L, (8. 21 ± 1.55 ) mmol/L, (8. 12 ± 1.65 ) mmol/L respectively in observation group and (9.70 ±1.71) mmol/L, ( 10.32 ± 1.43 ) mmol/L, (9. 88 ± 1.54) mmol/L respectively in control group. Insulin daily dosage was (35.0±9.5)U in observation group and (46.5 ±10.2)U in control group. There were 9 hypoglycemic events in control group and 2 in observation group. So the 2hPBG, insulin daily dosage and incidence of hypoglycemia between the two groups were statistically significant (P <0.05). There were no statistical difference in the FBG between the two groups (P>0.05). Conclusion Insulin Aspart 30 combined with Voglibose is proved to be a safe and effective therapy for type 2 diabetes mellitus with lower insulin dosage and incidence of hypoglycemia. Source


Lu W.,Dalian Medical University | Wei H.,Dalian Medical University | Li M.,Dalian Medical University | Wang H.,Third Peoples Hospital of Dalian | And 3 more authors.
Molecular Medicine Reports | Year: 2015

Cetuximab, an immunoglobulin G1 chimeric monoclonal antibody directed against the epidermal growth factor receptor, is currently considered to be the strategy with the most potential for the treatment of gastric cancer due to the low frequency of KRAS mutations in patients with gastric cancer. However, the therapeutic success of cetuximab in colorectal cancer (CRC) has demonstrated that the clinical effect of cetuximab is closely dependent not only on KRAS mutations, but also BRAF and phosphoinositide-3-kinase, catalytic, α polypeptide (PIK3CA) mutations. In the present study, the status of KRAS, BRAF and PIK3CA mutations in gastric cancer were investigated concomitantly in order to aid the selection of patients eligible for treatment with cetuximab. Mutations in KRAS (exon 2), BRAF (exon 15) and PIK3CA (exon 9 and exon 20) were retrospectively evaluated by high resolution melting analysis and DNA direct sequencing in samples from 156 patients with gastric cancer. Mutations in either KRAS or PIK3CA were identified in 13 samples (8.3%), 7 samples with KRAS mutations and 6 samples with PIK3CA mutations. No mutations in the BRAF gene were identified. The frequency of mutations in either KRAS or PIK3CA were significantly higher in patients without lymph node metastasis than those with. Furthermore, KRAS and PIK3CA mutations were mutually exclusive. The present study, therefore, suggested that it may be necessary to evaluate KRAS and PIK3CA mutations concomitantly for the selection of patients eligible for treatment with cetuximab. Source


Qu M.-H.,Third Peoples Hospital of Dalian | Zeng R.-F.,Sun Yat Sen University | Fang S.,Sun Yat Sen University | Dai Q.-S.,Sun Yat Sen University | And 2 more authors.
International Journal of Pharmaceutics | Year: 2014

Combination of more than one therapeutic strategy is the standard treatment in clinics. Co-delivery of chemotherapeutic drug and small interfering RNA (siRNA) within a nanoparticulate system will suppress the tumor growth. In the present study, docetaxel (DTX) and BCL-2 siRNA was incorporated in a PEGylated liposome to systemically deliver in a lung cancer model (A549). The resulting nanoparticle (lipo-DTX/siRNA) was stable and exhibited a sustained release profile. The co-delivery of therapeutic moieties inhibited the cell proliferation (A549 and H226) in a time-dependent manner. Moreover, the co-delivery system of DTX and siRNA exhibited a remarkable apoptosis of cancer cells with elevated levels of caspase 3/7 activity (apoptosis markers). Cell cycle analysis further showed remarkable increase in sub-G0/G1 phase, indicating increasing hypodiploids or apoptotic cells. Pharmacokinetic study showed a long circulating profile for DTX from lipo-DTX/siRNA system facilitating the passive tumor targeting. In vivo antitumor study on A549 cell bearing xenograft tumor model exhibited a remarkable tumor regression profile for lipo-DTX/siRNA with 100% survival rate. The favorable tumor inhibition response was attributed to the synergistic effect of DTX potency and MDR reversing ability of BCL-2 siRNA in the tumor mass. Overall, experimental results suggest that co-delivery of DTX and siRNA could be promising approach in the treatment of lung cancers. © 2014 Published by Elsevier B.V. Source


Liu Y.,Third Peoples Hospital of Dalian | Gong Y.-J.,Dalian Medical University
International Journal of Ophthalmology | Year: 2010

Aim; To learn the up-regulation of aquaporin protein 3 (AQP3) expression in the corneal epithelial healing process of mice by cyclosporin A(CsA) eye drops. Methods; Models were established in the mechanical curettage method of corneal epithelium in mice to observe the repair of corneal epithelium. Corneas were treated with AQP3 immunohistochemical staining to observe the expression of AQP3. Results; AQP3 expression could be seen in the basal cell layer of the cornea. After applications of 125,250,500, 1000mg/L CsA eye drops, the AQP3 expression was increased progressively. When corneal epithelium injury was treated with 500mg/L CsA eye drops, there was no statistical difference in healing size between the experimental group and control group 6 hours after injury, while 12,18,24 hours after injury there was a statistically significant difference (P<0.05). Conclusion: 500mg/L CsA eye drops can accelerate mice corneal epithelial damage repair by increasing the expression of AQP3. Source

Discover hidden collaborations